Page 4«..3456..1020..»

Category Archives: Global News Feed

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Posted: January 13, 2025 at 2:54 am

- Ascendis positioned to drive rapid revenue growth

Go here to see the original:
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Posted in Global News Feed | Comments Off on Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Posted: January 13, 2025 at 2:54 am

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028

Read the original:
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Posted in Global News Feed | Comments Off on Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Posted: January 13, 2025 at 2:54 am

Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy Endpoints in Phase 2 CLOVER-WaM Study for Relapsed/Refractory Waldenstrom’s Macroglobulinemia

Read more:
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Posted in Global News Feed | Comments Off on Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

argenx Highlights 2025 Strategic Priorities

Posted: January 13, 2025 at 2:54 am

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales

See more here:
argenx Highlights 2025 Strategic Priorities

Posted in Global News Feed | Comments Off on argenx Highlights 2025 Strategic Priorities

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Posted: January 13, 2025 at 2:54 am

TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) today announced that it has entered into a strategic collaboration with Klinge Biopharma GmbH (Klinge) and Formycon AG (FSE: FYB) for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea® (aflibercept) in Europe, excluding Italy, and in Israel.

Continue reading here:
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Posted in Global News Feed | Comments Off on Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Posted: January 13, 2025 at 2:54 am

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Read the original post:
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Posted in Global News Feed | Comments Off on Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Novartis Entresto® US patent upheld by US Court of Appeals

Posted: January 13, 2025 at 2:54 am

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combination patent.

Read more from the original source:
Novartis Entresto® US patent upheld by US Court of Appeals

Posted in Global News Feed | Comments Off on Novartis Entresto® US patent upheld by US Court of Appeals

Idorsia to call for a bondholder meeting

Posted: January 13, 2025 at 2:54 am

Ad hoc announcement pursuant to Art. 53 LR

More:
Idorsia to call for a bondholder meeting

Posted in Global News Feed | Comments Off on Idorsia to call for a bondholder meeting

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Posted: January 13, 2025 at 2:54 am

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024).

Read more:
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Posted in Global News Feed | Comments Off on Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

79,345 Orion Corporation A shares converted into B shares

Posted: January 13, 2025 at 2:54 am

ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE13 JANUARY 2025 at 9.50 EET

Go here to see the original:
79,345 Orion Corporation A shares converted into B shares

Posted in Global News Feed | Comments Off on 79,345 Orion Corporation A shares converted into B shares

Page 4«..3456..1020..»